Differential organ-specific tumor response to first-line immune checkpoint inhibitor therapy in non-small cell lung cancer—a retrospective cohort study

BACKGROUND: Immune checkpoint inhibitors (ICIs) possess remarkable clinical effectiveness in non-small cell lung cancer (NSCLC). Different immune profiles of tumors may play a key role in the efficacy of treatment with ICIs. This article aimed to determine the differential organ responses to ICI in...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Qi, Fang, Yujia, Li, Chunyu, Leong, Tracy L., Provencio, Mariano, Oh, In-Jae, Zhang, Zhemin, Su, Chunxia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989803/
https://www.ncbi.nlm.nih.gov/pubmed/36895937
http://dx.doi.org/10.21037/tlcr-23-83

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989803/
https://www.ncbi.nlm.nih.gov/pubmed/36895937
http://dx.doi.org/10.21037/tlcr-23-83

Ejemplares similares